Dr. John A. Belperio, MD

Dr. Belperio practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Belperio's NPI, 1285659482, was assigned on July 12, 2006. Dr. Belperio graduated from Lewis Katz School of Medicine in 1994. Dr. Belperio's California license number on file is A72669.

Dr. Belperio's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Belperio's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Belperio is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Belperio to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Belperio practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Belperio's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Belperio is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Belperio's licenses on file in 2 states: California and Michigan.

Dmand AI lists acute sinusitis, asthma, bronchitis, chronic lung disease, chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary fibrosis and pulmonary heart disease among the conditions Dr. Belperio treats.

CMS data shows 1,028 Medicare services from Dr. Belperio across 5 procedure codes in 2024, for 175 Medicare patients. Medicare paid $87,641 for them.

CMS counts 175 Medicare patients who saw Dr. Belperio in 2024. The largest group is 75 to 84, with 94 patients. 75% of them have high cholesterol, and 74% have copd. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Belperio's median patient age at 74, with 50% women.

In 2024, Dr. Belperio wrote 1,547 Medicare Part D claims for 138 patients. 61% of them were for generic drugs. CMS names the drug for 1,231 of them, across 28 drugs with 11 or more claims each, at $308,515 in total drug cost. In 2023, CMS named 1,368 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Belperio for performance year 2024, reported as part of a group. Dr. Belperio accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Belperio as offering telehealth.

Dmand AI links 25 papers to Dr. Belperio, published from 2008 to 2025. 2019 was the busiest year, with 6. Dr. Belperio's most frequent co-authors are Kevin Robert Flaherty, MD, Stephen Samuel Weigt, MD and Abbas Ardehali, MD.

Dmand AI links Dr. Belperio to 5 clinical trials, 2 of them phase 3 studies. Conditions studied include Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis and Bronchiolitis Obliterans Syndrome.

CMS Open Payments shows 407 general payments to Dr. Belperio from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $222,803. It also lists 11 research payments totaling $13,925 from 2018 to 2024.

Dmand AI lists 3 awards for Dr. Belperio, most recently Regional Top Doctor in 2014.

Dr. Belperio graduated from Lewis Katz School of Medicine in 1994.

Dr. Belperio is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.